Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

3.79
-0.0500-1.30%
Post-market: 3.850.0600+1.58%19:30 EDT
Volume:738.90K
Turnover:2.83M
Market Cap:118.59M
PE:-0.92
High:3.91
Open:3.85
Low:3.79
Close:3.84
52wk High:50.40
52wk Low:3.60
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.91
T/O Rate:4.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.54
PE(LYR):-1.33

Loading ...

Chimeric Therapeutics Suspended as It Negotiates Creditor Deals and Board Restructure

TIPRANKS
·
Yesterday

Have Insiders Sold Cutia Therapeutics Shares Recently?

Simply Wall St.
·
Yesterday

TScan Therapeutics Announces Executive Departures Amid Reorganization

TIPRANKS
·
Yesterday

Outlook Therapeutics Faces Nasdaq Minimum Bid Price Deficiency

TIPRANKS
·
Yesterday

Halozyme Therapeutics Adds James Daly to Board

TIPRANKS
·
Yesterday

Analyst Reiterates Buy on Quince Therapeutics, Maintaining Unchanged $98 Price Target Amid Advancing Pulmonary Pipeline

TIPRANKS
·
Yesterday

Whitehawk Therapeutics initiated with a Buy at Stifel

TIPRANKS
·
Yesterday

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

GlobeNewswire
·
Yesterday

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

GlobeNewswire
·
Yesterday

Sarepta Therapeutics is Maintained at Neutral by JP Morgan

Dow Jones
·
Yesterday

EPIRUS Therapeutics: Buy Rating Reiterated on EP-104GI’s Emerging Clinical Profile and Upcoming Phase 2b Catalyst; $16 Price Target Unchanged

TIPRANKS
·
Yesterday

Keros Therapeutics Advances DMD Trial for KER-065, Keeping Rare Disease Upside in Play

TIPRANKS
·
Yesterday

Damora Therapeutics Advances CALR-Targeted Antibody Into Early Clinical Testing

TIPRANKS
·
Yesterday

CytoMed Therapeutics Posts Narrower Interim Loss in June 2026 SEC Filing

TIPRANKS
·
Sep 30

Indaptus Therapeutics Extends Timeline for Private Placement Financing

TIPRANKS
·
Sep 30

Silexion Therapeutics Begins Global SIL204 Pancreatic Cancer Trial

TIPRANKS
·
Sep 30

Cutia Therapeutics to Launch Up to 30 Million Yuan Share Buyback

MT Newswires Live
·
Sep 30

Cutia Therapeutics Unveils Targeted Share Buyback to Signal Confidence

TIPRANKS
·
Sep 30

Thalia Therapeutics Accelerates RNA Strategy With Sanmirna Deal and Clinical-Stage Pipeline

TIPRANKS
·
Sep 30

Shield Therapeutics updates total voting rights and share capital

TIPRANKS
·
Sep 30